A MediCom Oncology Site
Create an account
Clinical Advisory Board
Clinical Pearls Podcasts
Clinical Case Snapshots
Clinical Expert Commentaries
Journal Club Library
2018 RRMM Symposium Replay
COVID-19 Resource Center
Criteria for Diagnosis
Revised International Staging System for Multiple Myeloma
Annual Meeting Highlights
Accredited E-Newsletter Series
Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context
Challenging Cases in RRMM Symposium Replay
Comorbid Patients with Multiple Myeloma: Considering All the Facts in Treatment Selection
--- Archives ---
RRMM Navigating New Treatment Paradigms
Clinical Dialogues™ in Multiple Myeloma
Clinical Discussion Series
Recognizing the Signs and Symptoms of MM in the Primary Care Setting
CE for Nurses
FAQ Library - Induction Therapy
What is the CyBorD regimen's safety and efficacy as a primary therapy?
Robert Z. Orlowski, MD, PhD
May 9, 2013
Dr. Robert Orlowski explains the CyBorD regimen and its safety and efficacy as an induction therapy.
What are the goals of induction therapy?
Jesus F. San Miguel, MD
February 16, 2010
A brief overview of complete response in patient subtypes of multiple myeloma.
Results 1 - 2 of 2
MediCom Worldwide, Inc. Links